Studies Enrolling Volunteers
- No prior diagnosis of dementia or psychiatric illness
- Lives independently
- No contraindications to MRI
- Ages: 50-79
Synaptic Therapy Alzheimer’s Research Trial (START)The START study tests an investigational treatment to see if it can safely slow memory loss from Alzheimer’s disease (AD). The study lasts about two years, and you will be asked to make about 24 visits to the study site to see doctors who will closely monitor your health. By participating, you or your loved one could be an important part of finding new treatments for people with AD.
| Research Study | Eligibility Criteria | Study Description |
|---|---|---|
| Emory Alzheimer's Disease Research Center Honor Research Registry Longitudinal study of changes in memory and other cognitive skills |
| |
| Brain Donation Program |
| The purpose of this research study is to follow individuals who have participated in ACTC and/or ATRI research studies, over the phone every 6 months, until the time of death. All participants who join this study are registered members of the ACTC Brain Donation Program. |
| The Alzheimer’s Disease Neuroimaging Initiative (ADNI4) |
| The ADNI study is a research project that looks at how different tests—like memory tests, brain scans, and genetics—are related to Alzheimer’s disease. It helps researchers understand the disease from the very beginning. The information collected will help design future studies to find better treatments for Alzheimer’s. |
| ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) |
| The ALLFTD study looks at people with a brain disease called frontotemporal dementia (FTD), including those who have it and family members who might get it. The goal is to learn how the disease changes over time and help with future treatments. The study has two parts: one does a full check-up every year, and the other collects only basic health info and body samples like blood or saliva. |
| Benfotiamine (Benfo) in Early (ADAPEX) |
| The BenfoTeam clinical trial will test if boosting thiamine in the brain can slow cognitive decline people with MCI and mild AD (a period of time also known as “early AD”) |
| Charlie and Harriet Shaffer Cognitive Empowerment Program (CEP) |
| The Charlie and Harriet Shaffer Cognitive Empowerment Program aims to provide people with Mild Cognitive Impairment (MCI) and their Care Partners and families with an opportunity to participate in comprehensive lifestyle programs that promote joy, purpose, health, and wellness. Members of the program will receive personalized assessments designed to empower them as they seek to implement healthy brain interventions. |
| Emory Healthy Aging Study (EHAS) |
| The Emory Healthy Aging Study is a longitudinal study focused on helping us better understand how we age and age-related disease through the creation of a large database of health history information provided by participants. |
| Emory Healthy Brain Study (EHBS) |
| The Emory Healthy Brain Study is a longitudinal sub-study of the Emory Healthy Aging Study focused on identifying the biomarkers of Alzheimer’s disease and other forms of dementia. |
| Goizueta Institute Biorepository Cognitive |
| |
| Heart Outcomes Prevention Evaluation (HOPE) |
| The study tests whether light and sound therapy can help slow down Alzheimer’s disease in people with mild to moderate symptoms. It checks for changes over 39 weeks. |
| Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) |
| This study looks at the differences between people who get Alzheimer’s disease early (before age 65), those who get it later, and older adults without memory problems. The goal is to better understand what causes Alzheimer’s and how it affects the brain. |
| HONOR/ Memory/ UDS |
| Memory at Emory is a longitudinal study designed to learn more about neurologic disorders. Criteria for participation includes individuals 70 years of age or older. |
| Pak- Alzheimer’s Disease (AD) |
| The PAK – AD study explores the impact of Citicoline (dietary supplement) on sleep health and cognition in persons diagnosed with Alzheimer’s disease confirmed from by medical record. |
| Memory & Sleep Research Study (PAK – Citosleep) |
| The PAK – Citosleep study explores the impact of Citicoline (dietary supplement) on sleep health and biomarkers (a marker of your condition) in persons with Mild Cognitive Impairment (MCI). |
| Precision Aging Network (PAN) | The Precision Aging Network seeks help to answer critical questions: What impacts healthy brain function as we age? How can optimal brain function be maintained across our entire lives? For you as an individual, how can we predict, prevent, or slow unwanted changes in cognition? | |
| STAND |
| |
| SuperAger |
| |
| Synaptic Therapy Alzheimer’s Research Trial (START) | The START study tests an investigational treatment to see if it can safely slow memory loss from Alzheimer’s disease (AD). The study lasts about two years, and you will be asked to make about 24 visits to the study site to see doctors who will closely monitor your health. By participating, you or your loved one could be an important part of finding new treatments for people with AD. |
Contact Us
Please contact our Senior Project Support Specialist for more information.
Detailed Descriptions of Research Studies and Clinical Trials
James Lah, MD, PhD
Clinical Core Leader, Emory Alzheimer's Disease Research Center
Felicia Goldstein, PhD
Clinical Core Co-Leader, Emory Alzheimer's Disease Research Center
The purpose of Honor is to have a group of volunteers who want to participate in future research studies on memory & thinking. By joining Honor you will learn about new research studies that are seeking volunteers. You will also receive our newsletter and invitations to educational events.
All Honor volunteers must have a “study partner” accompany them to their research visit. Your study partner will be asked questions about your memory and thinking. They will also be asked about your day to day functioning. A study partner is someone who has at least 10 hours of contact with you each week.
For more information about this research study, please call Samantha Heldenberg at 404-712-7542 or email shelden@emory.edu.
Allan Levey, MD, PhD
Director, Emory Alzheimer's Disease Research Center
Emory University Department of Neurology
Long-term study (2-4 years) being conducted as part of the Alzheimer’s Disease Neuroimaging Initiative to characterize changes in the brain associated with MCI and AD. Subjects will under multiple MRI and PET scans, lumbar puncture, blood draws and cognitive testing.
For more information about this research study, please call Becky Byram at 404-712-0195 or email rbyram@emory.edu.
Allan Levey, MD, PhD
This multinational study is using a placebo or the study drug, to determine safety and efficacy and to explore the dose response of this drug. In this 18-month study, a drug/placebo is infused biweekly (once every 2 weeks). Subjects will be from 2 clinical subgroups: MCI due to Alzheimer's disease (AD) or mild Alzheimer's disease dementia. Effectiveness of drug treatment will be assessed using cognitive tests, as well as biological markers (MRI, PET, CSF, blood).
For more information about this research study, please call Michelle Wiles at 404-778-0664 or email mkwiles@emory.edu.
Ihab Hajjar, MD
The study will consist of a screening period of up to 12 weeks in length following the signing of informed consent. Eligible patients will then undergo baseline visit assessments (Day 1) prior to receiving the first dose of blinded study drug (gantenerumab or placebo). Patients will continue in the double-blind treatment period for 104 weeks.
For more information about this research study, please call Aaron Milloy at 404-712-6855 or email aaron.m.milloy@emory.edu.
For more information about this research study, please call William Hu at 404-727-4174 or email wthu@emory.edu.
This study is the largest clinical research study every conducted it Atlanta. It is designed to further our scientific understanding of how we age so we can better understand, prevent and treat diseases of aging. To participate, simply sign up online at www.healthyaging.emory.edu, complete a brief health history questionnaire and occasionally respond to various surveys and complete online memory tasks.
For more information about this research study, please call Luke Maschinot at 404-727-1338 or email luke.j.maschinot@emory.edu.
Caregiving for a loved one with Alzheimer’s or another form of neurodegenerative disease is usually a new role. Some people gradually take on the role of caregiver as their spouse or parent has increasing memory or thinking problems. Others are thrust into the role. Perhaps your mother died who was caring of your father. Suddenly you become your father’s caregiver, a role for which you had no preparation.
When you have a family member with Alzheimer’s or another neurodegenerative disease there are new skills to learn and new resources that will be needed. It will be important to “plan for the future”.